药业新观察第1季度英文_精品文档.pdf
- 文档编号:3213955
- 上传时间:2022-11-20
- 格式:PDF
- 页数:12
- 大小:214.70KB
药业新观察第1季度英文_精品文档.pdf
《药业新观察第1季度英文_精品文档.pdf》由会员分享,可在线阅读,更多相关《药业新观察第1季度英文_精品文档.pdf(12页珍藏版)》请在冰豆网上搜索。
AWARDEDTOTHOMSONSCIENTFICLIMITED(THESCIENTIFICBUSNESSOFTHOMSONREUTERS)ExpertreviewfromThomsonReutersofthemostpromisingdrugschangingclinicalphase,receivingapprovalandlaunchedthisquarter,basedonthestrategicdataandinsightofThomsonReutersPharma,theworldsleadingpharmaceuticalcompetitiveintelligencesolution.THEONESTOWATCHAPHARMAMATTERSREPORT.AREviEwofJAnuARy-MARch2011.PublishEdJunE2011.ImageCopyrIght:
AlessandrobianchiPHARMAMATTERS|THEONESTOWATCHFormoreinformationonThomsonReutersPharmavisitoremailPHARMAMATTERS|THEONESTOWATCHInthefaceofexternalpressuressuchasacontinuingpooreconomy,theimpendingpatentcliff,andanincreasinglytoughregulatoryenvironment,Pharmacompaniesareseekingmorepartnershipopportunitiesthaneverbefore,especiallyatanR&Dlevel.Bysharingtherisks,businessesarehopingtoavoidthecostsofearlyorlatestagefailure.Partneringcanalsoallowcompaniestoaccessinnovativenewtechnologies,andthepharmaindustryisincreasinglyrecognizinghowimportantinnovationisinallareas,notjustR&D.However,whilepartneringcertainlycanbearewardingmethodofusheringaproductthroughthepipeline,dueconsiderationshouldgointoeverydeal.Overall,theindustryisexpectinggrowthduetotheincreasinghealthcareneedsofanagingpopulationandhigherincidenceofchronicdisease.ThiseditionofTheOnestoWatchcontainsexamplesofcompaniesjoiningforcestoadvancetheirproductsthroughtheR&Dprocess,includingHologicandKVPharmaceuticalsMakena,BaxterandDynPortsPerFluCelandGlaxoSmithKlineandChemoCentryxsCCX-832.Anti-canceragentsalsofeatureheavilyinthisissue,asinpreviousquarters,withthemostsignificantbeingYervoy,thefirsttherapyapprovedintheU.S.forunresectableormetastaticmelanomainover10years.LorusTherapeuticsLOR-253andBioMarinPharmaceuticalsBMN-110bothenteredphaseItrialsthisquarterandofferinterestinginnovativeapproachesintacklingcancer.Partneringisoneofthemajorinitiativesdrugdevelopersareutilizingtochangethewayresourcesareallocatedforportfoliomanagementandbusinessgrowth,andinthisissueweexaminesomeofthosepartneringsuccessstories.Letstakeacloserlookatthefivemostpromisingdrugslaunchedorreceivingapproval,andthenmovethrougheachclinicalphase,betweenJanuaryandMarch2011.PHARMAMATTERS|THEONESTOWATCHThEfivEMosTPRoMisingdRugslAunchEdoRREcEivingAPPRovAlDRUGDISEASECOMPANYMakenaPrematurelaborHologic/KVPharmaceuticalGraliseNeuralgiaDepomedYervoyMelanomaMedarexPREFLUCELInfluenzavirusinfectionBaxter/DynPortEdirolOsteoporosisChugai/TaishoWebeginthiseditionofTheOnestoWatchwithHologicandKVPharmaceuticalsmakena,whichinFebruary2011becamethefirstandonlyFDA-approvedtherapydesignedtoreducetheriskofprematurelabor(pretermbirth)inwomenwithahistoryofsingletonspontaneouspretermbirth.ThedrugwaslaunchedinMarch2011.Makena(formerlyknownasGestiva)isalong-actinginjectableformofthenaturally-occurringprogesterone17alpha-hydroxyprogesteronecaproate(17P)andaccordingtoitsmakersandhealthcareproviders,offersabreakthroughinthefightagainstpretermbirth,givinghopetothousandsofwomenaffectedbypretermbirth.USstatisticsforpretermbirth,definedasabirthatlessthan37completedweeksofpregnancy,revealthatoneineightbabiesisbornprematurelyandcostthecountry$26billionperyear.Furthermore,thelastquarterofacenturyhasseena35percentincreaseintherateofprematurebirths.Whilethecauseofprematurelaborisasyetunknown,recentresearchshowedthatsupplementingprogesteronelevelsinpregnantwomenwithahistoryofspontaneouspretermbirthenabledthemtoprolongtheirgestationperiodandreducecomplicationsforthemselvesandtheirbabies.Makenasapprovalwasbasedonamulticenter,double-blind,placebo-controlledNIH-fundedstudyinwhich463womenbetweenweek16and21ofpregnancyandwithahistoryofpretermbirthreceivedweeklyinjectionsofthedrugorplacebountildeliveryor37weeksgestation.A34percentreductioninpretermbirthratewasseeninMakena-treatedwomen,withresultingchildrenhavingsignificantlylowerratesofnecrotizingenterocolitis,intraventricularhemorrhage,useofsupplementaloxygenandmeannumberofdaysofrespiratorytherapy.Thedrugiscurrentlyindicatedonlyinwomenwithapriorspontaneoussingletonpretermbirthandnotintendedforuseinwomenwithmultiplegestationsorotherriskfactorsforpretermbirth.gralise,acontrolled-releasetabletformulationoftheanticonvulsantanalgesicgabapentin(Neurontin)isthesecondapproved/launcheddrugofinterestinthisissueofTheOnestoWatch.DepomeduseditsAcuFormgastricretentiondeliverytechnologytodevelopGraliseforthetreatmentofpostherpeticneuralgia(PHN),apersistentneuropathicpai
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 药业 观察 季度 英文 精品 文档
![提示](https://static.bdocx.com/images/bang_tan.gif)